PDC*line Pharma
About PDC*line Pharma
PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.
PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.
What does PDC*line Pharma do?
PDCline Pharma develops a proprietary allogeneic Plasmacytoid Dendritic Cell line pre-loaded with tumor-derived peptides to create off-the-shelf, antigen-specific immunotherapies for cancer treatment. This technology addresses the limitations of current dendritic cell therapies by providing a scalable and effective solution for inducing strong cytotoxic immune responses against various cancers, including lung cancer.
Where is PDC*line Pharma located?
PDC*line Pharma is based in La Tronche, France.
When was PDC*line Pharma founded?
PDC*line Pharma was founded in 2014.
How much funding has PDC*line Pharma raised?
PDC*line Pharma has raised 13300000.
- Location
- La Tronche, France
- Founded
- 2014
- Funding
- 13300000
- Employees
- 40 employees
- Major Investors
- Korea Investment Partners